Image 4_Analysis of the global burden and key risk factors of neonatal sepsis and other neonatal infections in 204 countries and territories, 1990–2021.jpeg حسب Caini Mu (20997938)

"…</p>Conclusion<p>The analysis indicates that while the global burden of NSNIs has decreased, the situation remains serious in Africa and Southeast Asia, with a continuing rise in the burden of NSNIs in the Eastern Mediterranean and Western Pacific regions in recent years. …"

Image 2_Analysis of the global burden and key risk factors of neonatal sepsis and other neonatal infections in 204 countries and territories, 1990–2021.jpeg حسب Caini Mu (20997938)

"…</p>Conclusion<p>The analysis indicates that while the global burden of NSNIs has decreased, the situation remains serious in Africa and Southeast Asia, with a continuing rise in the burden of NSNIs in the Eastern Mediterranean and Western Pacific regions in recent years. …"

Additional file 1 of MDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets حسب Karl Knipper (15016346)

"…Volcano plot of all detected proteins comparing the proteome of neoadjuvantly treated MDM2-amplified and non-amplified tumors. Grey: not significantly different expressed, blue: significantly decreased expression in neoadjuvantly treated MDM2-amplified tumors, red: significantly increased expression in neoadjuvantly treated MDM2-amplified tumors. …"

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"

DataSheet1_Efferocytosis dysfunction in CXCL4-induced M4 macrophages: phenotypic insights in systemic sclerosis in vitro and in vivo.docx حسب Erwan Le Tallec (19834785)

"…Additionally, circulating levels of CXCL4, a novel SSc biomarker, correlate with more severe fibrotic manifestations of the disease. …"

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"